|
Press Releases |
|
 |
|
Tuesday, July 29, 2025 |
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house discovered tyrosine kinase inhibitor, "LENVIMA(R)" (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma. more info >> |
|
Friday, July 25, 2025 |
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. more info >> |
|
Wednesday, July 23, 2025 |
|
Launch of Beova(R) Tablets in Thailand for Overactive Bladder |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, "KYORIN") announced today that Eisai (Thailand) Marketing Co., Ltd. ("Eisai Thailand"), a subsidiary of Eisai, has launched overactive bladder treatment Beova(R) Tablets (generic name vibegron) in Thailand more info >> |
|
Tuesday, July 22, 2025 |
|
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB;) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI(R)), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. more info >> |
|
Wednesday, July 16, 2025 |
|
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a humanized anti-human soluble amyloid B (AB) protofibril monoclonal antibody indicated for early Alzheimer's disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden; herein after, BioArctic), has received "The 9th Bioindustry Award" from the Japan Bioindustry Association (JBA). more info >> |
|
Monday, July 14, 2025 |
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dotinurad) in China as a treatment for Gout. more info >> |
|
Tuesday, July 8, 2025 |
|
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that it has been selected for the highest rating of "Supplier Engagement Leader" in the Supplier Engagement Rating by the global environmental non-profit organization CDP. more info >> |
|
Monday, June 2, 2025 |
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1) more info >> |
|
Wednesday, May 28, 2025 |
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
Wednesday, May 21, 2025 |
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 30, 2025 19:56 HKT/SGT
|
|
|
Hong Kong Shopping Festival Returns in August with Bigger and Better 2nd Edition
Jul 30, 2025 18:29 HKT/SGT
|
|
|
Production, Sales and Export Results for June, 2025
Jul 30, 2025 18:24 JST
|
|
|
Sales, Production, and Export Results for the First Half of 2025
Jul 30, 2025 18:06 JST
|
|
|
Introducing the Meshy 5 Preview: Smarter AI, Cleaner Models, Bigger Animation Potential
Jul 30, 2025 17:00 JST
|
|
|
Ongoing Share Buybacks Demonstrate Confidence, Shoucheng Holdings Boosts Market Expectations with Concrete Action
Jul 30, 2025 11:00 HKT/SGT
|
|
|
Collaborative Development of Ultra-Compact and Lightweight Satellite Communication User Terminals for Mobility with Mitsubishi Chemical, NICT, and TECHLAB
Jul 30, 2025 11:00 JST
|
|
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 29, 2025 23:59 HKT/SGT
|
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Jul 29, 2025 23:13 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide
Jul 29, 2025 20:00 JST
|
|
|
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 16:00 HKT/SGT
|
|
|
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"
Jul 29, 2025 14:30 JST
|
|
|
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year
Jul 29, 2025 13:15 HKT/SGT
|
|
|
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains
Jul 29, 2025 11:30 HKT/SGT
|
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
Jul 29, 2025 9:01 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|